Barcelona

• EQU-001 as an Add-On Drug for People with Focal Seizures while on Medication Ended
  2022-500302-18-00 4 Epilepsy
• A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-916 in … Ended
  2022-500691-59-00 4 Alzheimer's disease (AD)
• A trial to learn if andexanet alfa is safe and works to limit bleeding in people who take factor 10a inhibitors and urgently need surgery Ended
  2022-501353-37-00 5 Reversal of anticoagulation effect in patients on a FXa inhibitor (api
• A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors Ended
  2022-501474-19-00 7 Non-Small Cell Lung Cancer
• A Phase 1/2 Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of the Oral KIT Inhibitor THE-630 in Patients with Advanced Gastro … Ended
  2022-502087-21-00 7 Gastrointestinal Stromal Tumors (GIST)
• Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia Ended
  2022-502233-25-00 5 Schizophrenia
• Mavacamten Impact on Myocardial Structure in Obstructive Hypertrophic Cardiomyopathy Ended
  2022-502316-36-00 11 Symptomatic Obstructive Hypertrophic Cardiomyopathy
• A Phase 3, Open-Label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Activity, and Safety of Ravulizumab … Ended
  2022-502335-19-00 5 Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) or Atypical Hem
• C4971006: A Study to Learn About the Effects of 2 Study Medicines (Maplirpacept [PF-07901801] and Glofitamab) When Given Together in People … Ended
  2022-502822-41-00 9 Relapsed/Refractory Diffuse Large B Cell Lymphoma
• A Phase 2 Study of BMS-986315 and Nivolumab in Combination with Chemotherapy in Participants with First-line Stage IV or Recurrent NSCLC Ended
  2022-503007-22-00 4 Non-small Cell Lung Cancer
• A Phase 1/2 Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors Ended
  2022-503060-33-00 4 Advanced or Metastatic Solid Tumor Malignancies
• Study of Obeldesivir in Children and Adolescents With COVID-19 Ended
  2023-503282-27-00 10 COVID-19
• OXU-001 compared to Intravitreal Ozurdex for the Treatment of Diabetic Macular Edema Ended
  2023-503496-17-00 4 Diabetic Macular Edema (DME)
• LSTA1 Phase 2a basket trial in advanced solid tumors Ended
  2023-503740-14-00 4 Head and neck cancer
• A Randomized, Double-blind, Placebo-controlled, Phase 2/3 Study to Assess the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmaco … Ended
  2023-503926-37-00 10 Biliary Atresia, Post-hepatoportoenterostomy
• Phase 1/2 Study of Belzutifan Plus Palbociclib Versus Belzutifan in Advanced Renal Cell Carcinoma (RCC) Ended
  2023-504963-17-00 9 Advanced ccRCC
• Study of BMS-986466 with Adagrasib with or without Cetuximab in Participants with KRAS G12C-mutant Solid Tumors Ended
  2023-505070-15-00 9 Oncology, NSCLC and CRC
• A study to see how safe and effective the drug Luveltamab Tazevibulin (STRO-002) is in treating infants and children under 12 years old with … Ended
  2023-506240-16-00 9 Acute Myeloid Leukemia (AML)
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advan … Ended
  2023-506487-13-00 5 Hormone receptor-positive, her2-negative advanced/metastatic breast ca
• A Phase 1 Randomized Study to Evaluate the Effect of Food on the Bioavailability of BMS-986158 in Participants with Advanced Solid Tumors. Ended
  2023-506661-65-00 3 Advanced Solid Tumors
• A Phase 3 Double-masked, Randomized, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edem … Ended
  2023-507207-66-00 5 Diabetic Macular Edema (DME)
• A phase I study of [177Lu]Lu-EVS459 in patients with ovarian and lung cancers Ended
  2023-507674-41-00 1 Advanced high-grade serous ovarian cancer (OC)
• A Phase 2a multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Burfiralimab (hzVSF-v13) … Ended
  2023-507944-35-00 4 rheumatoid arthritis
• A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 days to less than … Ended
  2023-508217-17-00 5 Autosomal Recessive Polycystic Kidney Disease

Showing 3,337–3,360 of 3,391 trials